t( 15;17 )
Molecular Haematology
Description
The chromosomal translocation t( 15;17 ) has been shown to be important in clinical practice. This aberration is specific for acute promyelocytic leukaemia, and indicates the specific treatment by the differentiative agent all-trans retinoic acid ( ATRA ). The molecular consequence of this translocation is PML-RARa gene fusion. The are 3 breakpoint cluster regions, one at the 5'end and 2 at the 3' end of the PML gene, requiring amplification of 2 separate PCR's with different primers and Mg2+ concentrations. The polymerase chain reaction ( PCR ) is a rapid and powerful method for detection of cDNA after reverse transcription of mRNA. PCR efficiently detects the chromosomal translocation t( 15;17 ) and may also be used to detect minimal residual disease.
Indications
Used to monitor cases known to have t( 15;17 ).
Sample Type
5ml EDTA blood or bone marrow, less than 48 hrs old.
Turnaround Time
Within 4 weeks
Testing Frequency
As required.
External Notes
Level of detection 1 leukaemic cell in 103 normal cells.
Please note: the above information is subject to change and we endeavour to keep this website up to date wherever necessary.
Your contact for this test
You are enquiring about
t( 15;17 )